Skip to content

Collagen Injections for the Treatment of Acne Scars and Wrinkles

Pilot Study of Autologous Fibroblast Injection for Acne Scars, Forehead Lines, Lip Lines, Horizontal Neck Lines, and Static Crow's Feet

Status
Terminated
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01704209
Enrollment
4
Registered
2012-10-11
Start date
2013-04-30
Completion date
2013-06-30
Last updated
2021-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne Scars, Wrinkles

Brief summary

The purpose of this study is to find out if autologous (your own) fibroblast injections are effective for the treatment of acne scars and wrinkles.

Interventions

DRUGFibroblast Treatment
PROCEDUREVehicle

Sponsors

Northwestern University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Age 18 or over * Bilateral acne scars or have moderate to severe wrinkles * Subjects in good health * Subjects has the willingness and the ability to understand and provide informed consent for the use of their tissue and communicate with the investigator

Exclusion criteria

* Under 18 years of age * Pregnancy or lactation * recent Accutane use in the past 6 months * prone to hypertrophic and keloidal scarring * have excessively redundant skin in the treatment area or wrinkles longer than 20 cm total * have a history of autoimmune disorders, organ transplantation, cancer not in remission, active or chronic skin disease * have a history of basal-cell carcinoma * have previously received autologous fibroblast treatment * have undergone any confounding therapy in the lower two-thirds of the face within 1 year or any investigational treatment within 30 days. * have an allergy to collagen, bovine products, local anesthetics, gentamicin, or amphotericin B * subjects who are unable to understand the protocol or to give informed consent * subjects with mental illness

Design outcomes

Primary

MeasureTime frame
Change from baseline of rater's comparisons at 6 monthsBasline and 6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026